NextCure (NASDAQ:NXTC) vs. Moleculin Biotech (NASDAQ:MBRX) Head-To-Head Contrast

NextCure (NASDAQ:NXTC) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

NextCure has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Valuation and Earnings

This table compares NextCure and Moleculin Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84 million	($20.00)	-0.54
Moleculin Biotech	N/A	N/A	-$33.56 million	($32.75)	-0.07

NextCure is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

42.7% of NextCure shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 17.9% of NextCure shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NextCure and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-152.90%	-109.17%
Moleculin Biotech	N/A	N/A	-60.88%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NextCure and Moleculin Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1	0	3	0	2.50
Moleculin Biotech	1	0	2	0	2.33

NextCure currently has a consensus price target of $23.00, suggesting a potential upside of 114.55%. Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 848.28%. Given Moleculin Biotech’s higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than NextCure.

Summary

Moleculin Biotech beats NextCure on 6 of the 11 factors compared between the two stocks.

About NextCure

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.